Open Access Open Access  Restricted Access Subscription Access

The Impact of Drugs on Migraine: A Comprehensive Analysis

Muralinath E., Pooja Devi, Prasanta Chbukdhara, Sanjib Borah, Kalyan C., Archana Jain, Guruprasad M.

Abstract


MIGRAINE, a neurological disorder, manifested by severe headaches, frequently accompanied by nausea, sensitivity to light and sounds, influences millions of people worldwide. A very few drugs decrease the frequency and severity vof MIGRAINE attacks. Beta blockers are also helpful in decreasing migraine by controlling blood vessel constriction. Anti-depressants like amitryptalline are more useful to manage migraines because of their impact on serotonin levels, a neurotransmitter related to the migraine development. Anti-seizure drugs namely topiramate and valproate decrease migraine frequency. These drugs are involved regarding the modulation of neuronal excitability and influence the abnormal electrical activity in the brain that may contribute to migraines. Abortive drugs are used to decrease pain and symptoms particularly during a migraine attack. Non-steroidal anti-inflammatory drugs (NSAIDs) namely ibuprofen and naproxen sodium are also utilized as abortive treatments. These drugs decrease inflammation and block pain signals and provide relief for many individuals feeling migraines. Calcitonin gene _ related Peptide (CGRP) inhibitors play a role in storing migraine attacks. Mono clonal antibodies namely erenumab and fremanezunab, play a role in preventing migraine. Common side effects of migraine drugs include dizziness, fatigue and gastro_ intestinal issues. Finally it is decided that preventive drugs decrease the frequency and adversity of attacks, but an abortive drugs result in relief particularly during acute episodes.


Full Text:

PDF

References


Rose, F. C. (1995). The history of migraine from Mesopotamian to Medieval times. Cephalalgia, 15(15_suppl), 1-3.

Arnold, M. (2018). Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia, 38(1), 1-211.

Merikangas, K. R., Risch, N. J., Merikangas, J. R., Weissman, M. M., & Kidd, K. K. (1988). Migraine and depression: association and familial transmission. Journal of Psychiatric Research, 22(2), 119-129.

Devoto, M., Lozito, A., Staffa, G., D'Alessandro, R., Sacquegna, T., & Romeo, G. (1986). Segregation analysis of migraine in 128 families. Cephalalgia, 6(2), 101-105.

de Vries, B., Anttila, V., Freilinger, T., Wessman, M., Kaunisto, M. A., Kallela, M., ... & van den Maagdenberg, A. M. (2016). Systematic re-evaluation of genes from candidate gene association studies in migraine using a large genome-wide association data set. Cephalalgia, 36(7), 604-614.

Riant, F., Ducros, A., Ploton, C., Barbance, C., Depienne, C., & Tournier-Lasserve, E. (2010). De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine. Neurology, 75(11), 967-972.

Jen, J. C., Kim, G. W., Dudding, K. A., & Baloh, R. W. (2004). No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Archives of neurology, 61(6), 926-928.

Costa, C., Prontera, P., Sarchielli, P., Tonelli, A., Bassi, M. T., Cupini, L. M., ... & Calabresi, P. (2014). A novel ATP1A2 gene mutation in familial hemiplegic migraine and epilepsy. Cephalalgia, 34(1), 68-72.

Ebrahimi-Fakhari, D., Saffari, A., Westenberger, A., & Klein, C. (2015). The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain, 138(12), 3476-3495.

Jarvis, S. E., & Zamponi, G. W. (2005). Masters or slaves? Vesicle release machinery and the regulation of presynaptic calcium channels. Cell calcium, 37(5), 483-488.

Suzuki, M., Van Paesschen, W., Stalmans, I., Horita, S., Yamada, H., Bergmans, B. A., ... & Seki, G. (2010). Defective membrane expression of the Na+-HCO3− cotransporter NBCe1 is associated with familial migraine. Proceedings of the National Academy of Sciences, 107(36), 15963-15968.

Lee, H. N., Eom, S., Kim, S. H., Kang, H. C., Lee, J. S., Kim, H. D., & Lee, Y. M. (2016). Epilepsy characteristics and clinical outcome in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). Pediatric neurology, 64, 59-65.

Hansen, J. M., Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., ... & Charles, A. (2012). Migraine headache is present in the aura phase: a prospective study. Neurology, 79(20), 2044-2049.

Stam, A. H., Kothari, P. H., Shaikh, A., Gschwendter, A., Jen, J. C., Hodgkinson, S., ... & Ferrari, M. D. (2016). Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations. Brain, 139(11), 2909-2922.

Martin, V. T., & Behbehani, M. M. (2001). Toward a rational understanding of migraine trigger factors. Medical Clinics of North America, 85(4), 911-941.

Kelman, L. (2007). The triggers or precipitants of the acute migraine attack. Cephalalgia, 27(5), 394-402.

Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache: The Journal of Head and Face Pain, 41(7), 646-657.

Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5), 343-349.

Vetvik, K. G., & MacGregor, E. A. (2017). Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. The Lancet Neurology, 16(1), 76-87.


Refbacks

  • There are currently no refbacks.